Future research must prioritize head-to-head trials (e.g., tirzepatide versus retatrutide) and validate predictive biomarkers (e.g., GDF15 for anti- inflammatory responses) to advance precision medicine
This new study published in #EHJVSHD suggests that moderatesevere TR is not just a marker of advanced disease, but may also represent a practical barrier to the implementation of GDMT Among 858 patients hospitalized for acute decompensated HFrEF, moderatesevere TR was independently associated with a lower likelihood of reaching 50% of target dose at 1 year for RASi/ARNi and beta-blockers but not MRAs
This surgery is not exempt from complications: persistence of hypoglycaemia episodes, nausea and vomiting or limitations in oral tolerance, weight regain and gastro-oesophageal reflux
Although ROS benefit physiological processes, such as removal of infectious pathogens, healing, and repair of tissues (Tovar-y-Romo et al., 2016